B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+2.32%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.92B
AUM Growth
+$79.1M
Cap. Flow
-$672M
Cap. Flow %
-22.98%
Top 10 Hldgs %
45.84%
Holding
68
New
6
Increased
13
Reduced
17
Closed
13
Avg Time Held
1.3 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
CAI icon
Caris Life Sciences
CAI
+$197M
2
KRYS icon
Krystal Biotech
KRYS
+$48M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
4
INSP icon
Inspire Medical Systems
INSP
+$31.9M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$29.2M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$65.9M
2
BPMC icon
Blueprint Medicines
BPMC
+$38.9M
3
IRTC icon
iRhythm Holdings
IRTC
+$33.1M
4
BCAX icon
Bicara Therapeutics
BCAX
+$28.2M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 71.51%
2 Miscellaneous 28.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
51
Ironwood Pharmaceuticals
IRWD
$595M
– –
-6,622,584
Closed -$9.74M –
SRPT icon
52
Sarepta Therapeutics
SRPT
$1.77B
– –
-234,500
Closed -$15M –
TRVI icon
53
Trevi Therapeutics
TRVI
$1.75B
– –
-72,083
Closed -$453K –
SKYE icon
54
Skye Bioscience
SKYE
$6.73M
– –
-103,217
Closed -$1.31M –
BCAX icon
55
Bicara Therapeutics
BCAX
$1.15B
– –
-2,162,803
Closed -$28.2M –
BBNX icon
56
Beta Bionics
BBNX
$912M
– –
-140,000
Closed -$1.71M –
MTSR
57
DELISTED
Metsera Inc
MTSR
– –
-175,000
Closed -$4.76M –
AARD icon
58
Aardvark Therapeutics
AARD
$85.1M
– –
-500,000
Closed -$3.75M –
1 2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2025 Portfolio in Review

As of Q2 2025, Braidwell held 68 positions worth $2.92B, up 2.8% from $2.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Braidwell withdrew a net $672M in Q2 2025, closing 13 positions and reducing 17 holdings. Its most notable exit was Blueprint Medicines, an estimated $38.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 67% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Caris Life Sciences worth $195M.

  • Braidwell's largest Q2 2025 buy was Caris Life Sciences: 7,316,142 shares worth $195M.
  • Braidwell added most to Krystal Biotech in Q2 2025, an estimated $48M increase.
  • Braidwell's biggest Q2 2025 reduction was Transmedics, cutting an estimated $65.9M.
  • Braidwell fully exited Blueprint Medicines in Q2 2025, selling an estimated $38.9M.
  • Braidwell's ten largest holdings make up 46% of its $2.92B portfolio in Q2 2025.
  • Braidwell opened 6 new positions and closed 13 in Q2 2025.
  • Braidwell's portfolio value rose 2.8% quarter-over-quarter to $2.92B.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.